NNHLA Quarterly Report January 2021 to December 2023 (published July 2024)

The purpose of the National non-Hodgkin lymphoma Audit (NNHLA) is to evaluate the patterns of care and outcomes for people diagnosed with non-Hodgkin lymphoma (NHL) in England and Wales, and to support services to improve the quality of their care. More details of the audit aims and scope can be found on our web page.

The NNHLA is part of the National Cancer Audit Collaborating Centre (NATCAN), the home of ten national cancer audits in England and Wales. This national centre of excellence was established to strengthen cancer services by evaluating the process of diagnosis and treatment, and outcomes in multiple cancer sites.

The quarterly report published by the the NNHLA team provides an overview of the quality of key data items captured in the Rapid Cancer Registration Dataset (RCRD), and the Cancer Outcomes and Services Dataset (COSD), for people diagnosed in NHS trusts with non-Hodgkin lymphoma in England between the 1st of January 2023 and the 31st of December 2023.

A high level summary describing the characteristics of people diagnosed with NHL is also provided at NHS trust, Cancer Alliance and national levels and this covers the time period of the 1st of January 2022 to 31st of December 2023.

this quarterly report, which focuses on data quality, is intended to highlight to trusts where data submissions to COSD could be improved to enable better reporting on performance indicators in the future. Subsequent quarterly reports will also report on performance indicators relevant to non-Hodgkin lymphoma.

Click on the button below to download your copy of the Quarterly Report.

NNHLA Quarterly Report, January 2021 to December 2023

Why does the report focus on data completeness/quality?

We have initially focused on data completeness as this aspect of data quality underpins what we can reliably and robustly report as an audit. Going forward, the team will continue development work, in consultation with stakeholders, to determine which performance indicators are appropriate for quarterly reporting.

We encourage all provider teams to review their data completeness and make improvements as required. This will increase the number of people diagnosed with NHL that we can include in analyses and increase the range of analyses we can conduct. By focusing exclusively on data completeness for this report, we aim to shine a spotlight on areas where improvements are needed.

The National Disease Registration Service (NDRS) has regional Data Liaison Managers who support NHS teams submitting cancer data to NDRS with advice and support on data improvement initiatives. We encourage trusts to get in touch with this team for support and advice. Contact details can be found here.

Data sources used in this report

In England, NATCAN receives information from the National Cancer Registration and Analysis Service (NCRAS), part of the NDRS, NHS England. NDRS collects patient-level data from all NHS acute providers on people diagnosed with cancer using a range of national data-feeds. This includes the Cancer Registration datasets and the Cancer Outcomes and Services Dataset (COSD). COSD data are submitted to the NDRS on a monthly basis via Multidisciplinary Team electronic data collection systems.

For this quarterly report, the NNHLA utilised data from the Rapid Cancer Registration Dataset (RCRD) and the COSD.

The RCRD dataset used is compiled mainly from COSD records and is made available more quickly than the complete cancer registration dataset. However, the speed of production means that the range of data items is limited and several standard data items in the complete registration dataset are unavailable. We therefore report data completeness for a few select items from the COSD that are not reported in the RCRD. The RCRD also does not have complete coverage of all people diagnosed with NHL in England during the reporting period.

Results on data completeness are reported for a one year period, rather than quarterly, to ensure sufficiently large numbers of records are included to produce reliable estimates at trust level.

A two-year period was selected when reporting the characteristics of people diagnosed with NHL to avoiding reporting based on small numbers at the trust level, particularly for categorical variables with multiple subgroup options.

The NNHLA report allocates records to NHS organisations based on the “trust at diagnosis” recorded within the RCRD dataset.

How have we chosen these specific data items to focus on?

The specific data completeness items were chosen in collaboration with the audit’s clinical and methodological experts.

The audit cohort was selected based on ICD-10 codes C82-C86 or C88 (follicular and non-follicular lymphoma, mature T/NK-cell lymphomas, malignant immunoproliferative diseases, other and unspecified types of non-Hodgkin lymphoma), or ICD-10 code C91 in combination with any of the eligible ICD-0-3 codes listed on the ICD codes sheet (chronic lymphocytic leukaemia of B-cell type). Diagnoses based on death certificate were excluded.

Ethnicity was chosen as we would like to thoroughly explore inequalities in cancer care, which is a priority for NHS England. to enable this, it is important that every person diagnosed with NHL has ethnicity accurately recorded.

Performance status was chosen as it is important across cancers for assessing the eligibility of people diagnosed with NHL for different treatments.

For any queries relating to the audit, please email [email protected].

Last updated: 11 July 2024, 9:43am